Authors
Latest:
Bridging Communication Gaps: Comprehensive Care for Upper GI Cancer TreatmentExperts discuss how to facilitate open communication among the patient, caregivers, and the multidisciplinary team to ensure comprehensive care and alignment on treatment goals.
Latest:
Elizabeth Aronson Walks Through the Data Supporting Elranatamab Approval in Multiple MyelomaElizabeth Aronson, MSN, FNP-BCN, OCN, shares what stood out to her about the phase 2 MagnetisMM-3 trial assessing elranatamab in multiple myeloma.
Latest:
Peripheral Neuropathy Treatable With Teliso-V in C–Met-High NSCLCToxicities related to Teliso-V are manageable for patients with c-Met overexpressing non-small cell lung cancer, according to Jonathan Goldman, MD.
Latest:
Five Researchers Awarded Pilot Project FundingEvery year, Huntsman Cancer Institute receives funding from the American Cancer Society to support the promising research of junior faculty.
Latest:
Rx Road Map: Abemaciclib (Verzenio)Sarah Montini, BSN, RN, OCN, provides an in-depth look at abemaciclib for the treatment of patients with breast cancer in a downloadable reference sheet.
Latest:
Unlocking Bladder Cancer: A Guide to Effective Diagnosis and StagingExperts share insights on standard work-up and staging practices for a patient with newly diagnosed bladder cancer.
Latest:
Hilda Haynes-Lewis and Rosaleen Bloom on Financial Toxicity and Workplace Stressors for Patients Undergoing RadiationHilda Haynes-Lewis, PhD, ANP-BC, AOCNP; and Rosaleen Bloom PhD, APRN, ACNS-BC, AOCNS, discuss the ways a cancer diagnosis can impair an individual’s ability to work normally.
Latest:
Complementary Supportive Care Can Go Far for Patients With CancerGetting to the root of patients’ issues can provide support for their cancer journey through accessible means, says Heather Jackson, PhD, APRN, FNP-BC, NEA-BC, FAA-NP.
Latest:
Tarlatamab Yields Response in Real-World ES-SCLC PopulationMost patients demonstrated at least partial response to tarlatamab in a real-world population with extensive-stage small cell lung cancer.
Latest:
Niraparib-Based Triplet Therapy Offers OS Advantage in BRCA1/2+ mCRPCThe median overall survival with niraparib, abiraterone acetate, and prednisone was 30.4 months vs 28.6 months with abiraterone acetate and prednisone alone.
Latest:
Melanie Darvish on Receiving an ONS Scholarship and What it Means to Be An Oncology NurseMelanie Darvish, BSN, RN, shares her experience attending the Oncology Nursing Society (ONS) Congress with an ONS Scholarship.
Latest:
Many Patients Are Under-Sedated During End-of-Life Cancer CareDavid Hui, MD, MSc, from The University of Texas MD Anderson Cancer Center, discusses findings indicating that patients with agitated delirium may be under-sedated, in accordance with their personalized sedation goal.
Latest:
Goodman Highlights Potential Benefit of SBRT in Locally Advanced Pancreatic CancerKaryn A. Goodman, MD, MS, provides perspective on the potential advantages of stereotactic body radiation therapy in locally advanced pancreatic cancer.
Latest:
A Multidisciplinary Approach Improves a Patient’s Experience With Colon CancerEarly coordination with multiple specialty teams can maximize outcomes and improve quality of life for patients with complex metastatic disease.
Latest:
Supporting Patients Through Treatment for Advanced NSCLCPanelists discuss how dose modifications for ALK inhibitors can significantly improve quality-of-life issues such as brain fog and weight gain while maintaining disease control, emphasizing the importance of multidisciplinary team support, including palliative care from diagnosis.
Latest:
Subcutaneous Daratumumab May Be More Feasible for Older Patients With MMSubcutaneous daratumumab makes treatment a faster and more tolerable process for patients with multiple myeloma, according to an expert.
Latest:
Final Thoughts and Hope for a CurePanelists emphasize the importance of multidisciplinary collaboration, patient education, and advocacy in managing multiple myeloma while expressing optimism about emerging therapies like CAR T cells that offer deeper remissions and improved quality of life.
Latest:
How I Counsel Patients About Lung Cancer ScreeningA lung cancer screening navigator offers their perspective on shared decision-making.
Latest:
Subcutaneous Daratumumab Reduces Smoldering Myeloma ProgressionNew AQUILA data show PFS improvement in patients with smoldering multiple myeloma who were treated with subcutaneous daratumumab vs active monitoring.
Latest:
Sherry Adkins Talks Primary Care Provider Communication Following CAR T-cell TherapySherry Adkins, MSN, ANP-C, discusses some key considerations in ensuring quality patient care after they have completed CAR T-cell therapy at a specialized center.
Latest:
Dose Reductions Possible for Tivozanib With and Without Nivolumab for RCCKaty Beckermann, MD, PhD, explained that oncology nurses and APPs should be ready to administer and explain dose modifications for patients with RCC.
Latest:
Grace Choong and Matthew Goetz On the Impact of Adjuvant Endocrine Therapy Omission in ER+ Positive Breast CancerGrace Choong, MD; and Matthew Goetz, MD, discuss the effect of omitting adjuvant endocrine therapy for patients with estrogen receptor–positive breast cancer who were treated with neoadjuvant chemotherapy.
Latest:
Considerations for Premenopausal Women With TNBCTriple-negative breast cancer often occurs in women younger than 40.
Latest:
Low and Maldonado on Leveraging Wearable Devices to Improve Inpatient AmbulationSarah Low RN, MSN, OCN, CMSRN; and Claudia Maldonado-Howell, RN, MSN, FNP, BS, CMSRN, discuss their research on wearable technology.
Latest:
Life After CAR T Therapy: Insights for Patients and Referring OncologistsThis video segment focuses on key elements of patient education and support for long-term CAR-T survivors, strategies to maintain quality of life and manage late effects, differences in supportive care needs between ide-cel and cilta-cel recipients, and approaches to fostering collaboration between academic centers and community practices for optimal long-term care.
Latest:
Brianna Lutz on How to Improve Nurse Responsiveness on an Inpatient Oncology UnitBrianna Lutz, MSN, RN, OCN, discusses a red-and-green dot hourly column that shows which patients with cancer have been attended to in the past hour.
Latest:
Adverse Events of Menin Inhibitors in AML: What Nurses Should KnowGhayas C. Issa, MD, MS, discusses key adverse events of menin inhibitors in NPM1-mutated and KMT2Ar AML.
Latest:
Kelley Rone on the Evolving Role of Immunotherapy in GI CancersKelley A. Rone, DNP, RN, AGNP-c, discusses the advantages associated with immunotherapy in the treatment of patients with gastrointestinal cancers.
Latest:
How to Give Subsequent Therapy for Older Patients With Breast Cancer on CDK4/6 InhibitorsTreatment decisions for older adults after CDK4/6 inhibitors should be tailored, explained Courtney Moore, APRN, FNP-C, OCN.
